Dignify reports clearance to begin DTI-117 study; human results are still ahead

Dignify Therapeutics announced on October 7 that the FDA had cleared its Investigational New Drug application for DTI-117. The company describes this as allowing first-in-human evaluation of its investigational peptide. This brief attributes the clearance to the sponsor's announcement; it is not a separate FDA approval notice or evidence of a product authorized for routine treatment.

DTI-117 is a short-acting peptide and neurokinin-2 receptor agonist being developed for neurogenic bowel dysfunction and other bowel or bladder voiding disorders. The company's development goals are not established clinical benefits. Findings about controlled emptying in animal models do not show that the candidate is effective or safe in people.

The announced Phase 1 study is randomized, double-blind and placebo-controlled, using a single-ascending-dose design in healthy volunteers. It is planned to assess safety, tolerability and pharmacokinetics after intramuscular administration. The initial population is not patients with neurogenic bowel dysfunction, and the announcement does not give a participant count or report completed human outcomes.

The October 7 release anticipates the first participant in November 2026 and preliminary results from initial cohorts in early 2027. Those are forward-looking sponsor plans, not confirmation that a participant has been treated or that results are available. The current pipeline also describes a possible later sublingual formulation; that is separate from the route in the first study.

Dignify says the study is NIH-funded and identifies National Institute of Neurological Disorders and Stroke award U44NS129628. The release states that its content is the company's responsibility and does not necessarily represent NIH's official views. Funding support does not establish that the drug works or has received marketing approval.

Limits: this is an early clinical-development milestone, with no efficacy result, long-term safety conclusion or demonstrated benefit for people with neurological conditions. No dosing, administration or purchasing instructions are provided. It is not a recommendation to seek an unapproved product or replace existing care; discuss bowel and bladder symptoms with a licensed clinician.